Cardiff Oncology, Inc.
Close on Oct 19, 2026
- Market cap
- $60.58M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | During market hours | $104.00K | $-0.14 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | During market hours | $41.00K | $-0.18 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | During market hours | $120.00K | $-0.17 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 29, 2025 | During market hours | $121.00K | $-0.21 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | During market hours | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | During market hours | $165.00K | $-0.25 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 2, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 29, 2024 | During market hours | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 2, 2023 | During market hours | – | – | – |
Press releases
Announcements Cardiff Oncology filed with the SEC
Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Cardiff Oncology Announces $10 Million Registered Direct Offering
Material agreement · Other events · EX-99.1 to Form 8-K
June 3, 2026 Interim Results from the Randomized, Controlled Phase 2 CRDF-004 Trial Onvansertib + SoC Chemo/Bevacizumab in First-Line RAS-Mutated mCRC
Regulation FD disclosure · EX-99.1 to Form 8-K
Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth
Executive or director change · Other events · EX-99.1 to Form 8-K
FEBRUARY 2026 Company Overview The Onvansertib Opportunity
Regulation FD disclosure · EX-99.1 to Form 8-K
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development
Executive or director change · Other events · EX-99.1 to Form 8-K
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC
Executive or director change · Other events · EX-99.2 to Form 8-K
Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
JULY 29, 2025 CRDF-004 Trial Update 1st Line RAS-mutated mCRC
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)
Results of operations · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS -mutated mCRC
Executive or director change · Other events · EX-99.1 to Form 8-K
Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering
Material agreement · Other events · EX-99.1 to Form 8-K
DECEMBER 10, 2024 CRDF-004 Trial 1st Line RAS-mutated mCRC Initial Data Release
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Adopted on May 30, 2024
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
Regulation FD disclosure · EX-99.1 to Form 8-K
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Cardiff Oncology Announces First Patient Dosed in Randomized First-line
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
JAN UARY 2 0 2 4 Company Overview The Onvansertib Opportunity
Regulation FD disclosure · EX-99.1 to Form 8-K
Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
NOVEMBER 2, 2023 Q3 2023 Financial Results and Business Update
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Pancreatic Cancer and Small Cell Lung Cancer Program Updates
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update
Results of operations · Charter or bylaw amendment · EX-99.1 to Form 8-K
AU GU ST 7 , 2 0 2 3
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Other events · EX-99.1 to Form 8-K
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Other events · EX-99.1 to Form 8-K
Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer
Executive or director change · Other events · EX-99.1 to Form 8-K